Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03120936 · ClinicalTrials.gov registry record · Phase 4
The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community
A Phase 4 study of Pre-exposure Prophylaxis and Transgender Persons, sponsored by Public Health Foundation Enterprises.
- Completed
- Registry status
- Phase 4
- Development phase
- 158
- Enrollment target
- 5
- Study locations
NCT03120936 is a Phase 4 study of Pre-exposure Prophylaxis and Transgender Persons that has completed, run by Public Health Foundation Enterprises. The registered enrollment target is 158 participants, below the 180-participant average among 12 other Pre-exposure Prophylaxis trials with a reported enrollment target (12% lower). The trial reports 5 study locations across 1 state.
The verdict
NCT03120936, a Phase 4 study of Pre-exposure Prophylaxis and Transgender Persons, has completed, sponsored by Public Health Foundation Enterprises.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 158 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Stay Study is a multi-site, open-label HIV pre-exposure prophylaxis (PrEP) demonstration project for advancing PrEP delivery in the San Francisco Bay Area Transgender Community. Approximately 188 HIV-uninfected participants will be enrolled at 4 sites in San Francisco and Fremont and will be provided Truvada to take orally once daily as PrEP.
Conditions Studied
Interventions
- DRUG Emtricitabine / Tenofovir Disoproxil Oral Tablet
- BEHAVIORAL PrEP support
Study Locations (5)
California
- Tri-City Health Center - Fremont
- Bridge HIV, San Francisco Department of Public Health - San Francisco
- Tom Waddell Urban Health Clinic - San Francisco
- San Francisco Community Health Clinic - San Francisco
- Castro-Mission Health Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2017-08-08 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03120936
The ClinicalTrials.gov registry entry for NCT03120936 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 12 other Pre-exposure Prophylaxis trials with a reported enrollment target (12% lower). The listed sponsor is Public Health Foundation Enterprises, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pre-exposure Prophylaxis appearing as the primary indexed condition, and to 2 interventions - of which Emtricitabine / Tenofovir Disoproxil Oral Tablet is the first listed.
NCT03120936 reports 5 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03120936 about?
NCT03120936 is a clinical study titled "The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community". The Stay Study is a multi-site, open-label HIV pre-exposure prophylaxis (PrEP) demonstration project for advancing PrEP delivery in the San Francisco Bay Area Transgender Community. Approximately 188 HIV-uninfected participants will be enrolled at 4 sites in San Francisco and Fremont and will be pro...
What is the current status of trial NCT03120936?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 158 participants. The study started on 2017-08-08. Estimated completion is 2020-12-01.
What conditions does trial NCT03120936 study?
This clinical trial studies the following conditions: Pre-exposure Prophylaxis, Transgender Persons.
What interventions are being tested in trial NCT03120936?
The interventions under investigation include: Emtricitabine / Tenofovir Disoproxil Oral Tablet (DRUG), PrEP support (BEHAVIORAL).
Who is sponsoring clinical trial NCT03120936?
This trial is sponsored by Public Health Foundation Enterprises, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03120936 being conducted?
This trial has 5 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pre-exposure Prophylaxis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence
COMPLETED · Phase 4
-
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
RECRUITING · NA
-
Stick2PrEP Cisgender Women and Trans Individuals
RECRUITING · NA
-
Predictors of Health Service Utilizations Among Key Population in Washington DC
RECRUITING
-
Gathering Online for Dialogue and Discussion to Enhance Social Support
RECRUITING · NA
-
Case Management Dyad
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.